1[1]Pegram M,Hsu S,Lewis G,et al.Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers[J].Oncogene,1999,18:2241-2251.
2[2]Baselga J,Norton L,Albanell J,et al.Recombinant humanized antiHER2 antibody(Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts[J].Cancer Res,1998,58:2825-2831.
3[3]Leyland-Jones B,Hemmings F,Amold A,et al.Ayoub JP.Pharmacokinetics of Herceptin Administered with Paclitaxel every three weeks[J].Breast Cancer Res and Treat,2000,64:124.
4[4]Vogel C,Cobleigh M,Tripathy D,et al.First-line single-agent Herceptin (H) therapy for women with HER2-overexpressing metastatic breast cancer (MBC)[J].Eur J Cancer,2000.36(Suppl5):2000,S53.
